Elite in Prostate Cancer

Stephane Supiot

Nantes, FR 
Elite in Prostate Cancer
Nantes, FR 
OverviewLocationsClinical Research

Overview

Stephane Supiot practices in Nantes, France. Ms. Supiot is rated as an Elite expert by MediFind in the treatment of Prostate Cancer. Her top areas of expertise are Prostate Cancer, Ependymoma, Glioma, Prostatectomy, and Orchiectomy.

Her clinical research consists of co-authoring 263 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 142 articles and participated in 5 clinical trials in the study of Prostate Cancer.

Gender
Female

Locations

Nantes, France
Other Locations
Saint Herblain, France
Rene, France
St Herblain, Sete, France
Paris, France
1 Rue D'Amiens, Rouen, 76000, France
Angers, France
Dijon, France
CLCC Eugène Marquis
Rennes, France
3, Rue De La Porte De L'Hôpital, Strasbourg, 67065, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients
An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Radiation, Drug
Study Drugs: Apalutamide, Luteinising Hormone Releasing Hormone agonist
Study Phase: Phase 3
Phase I/II Multi-center Study Evaluating the Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence After External Radiation Therapy
Phase I/II Multi-center Study Evaluating the Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence After External Radiation Therapy
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2024
Intervention Type: Other, Radiation, Drug
Study Drugs: Abiraterone acetate, Docetaxel
Study Phase: Phase 3
Phase IIIb Randomized Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer. A Joint Study of the EORTC ROG and GUCG
Phase IIIb Randomized Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer. A Joint Study of the EORTC ROG and GUCG
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2024
Intervention Type: Drug, Radiation
Study Drugs: Degarelix, GnRH agonist
Study Phase: Phase 3
Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery
Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery
Enrollment Status: Completed
Publish Date: May 19, 2022
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Prednisone
Study Phase: Phase 1/Phase 2
SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
Enrollment Status: Terminated
Publish Date: April 14, 2022
Intervention Type: Radiation, Drug
Study Drug: Metformin
Study Phase: Phase 2
Hypofractionated Stereotactic Radiation Treatments (SBRT) on Children, Teenagers and Young Adults Malignant Tumors
Hypofractionated Stereotactic Radiation Treatments (SBRT) on Children, Teenagers and Young Adults Malignant Tumors
Enrollment Status: Completed
Publish Date: March 08, 2022
Intervention Type: Radiation
Study Phase: Not Applicable
View 6 Less Clinical Trials

263 Total Publications

French recommendations from the AFU Cancer Committee for prostate cancer 2025 Summary of changes.
French recommendations from the AFU Cancer Committee for prostate cancer 2025 Summary of changes.
Journal: The French journal of urology
Published: October 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Supiot's expertise for a condition
ConditionClose
View All 28 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile